Cytokinetics, Incorporated (CYTK)
-NasdaqCM 1.20 
0.01(0.84%) May 17, 4:00PM EDT
| Prev Close: | 1.19 |
|---|
| Open: | 1.19 |
|---|
| Bid: | 0.98 x 500 |
|---|
| Ask: | 1.19 x 5000 |
|---|
| 1y Target Est: | 3.63 |
|---|
| Beta: | 1.62 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 1.16 - 1.21 |
|---|
| 52wk Range: | 0.57 - 1.46 |
|---|
| Volume: | 776,099 |
|---|
| Avg Vol (3m): | 1,210,090 |
|---|
| Market Cap: | 178.34M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.35 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cytokinetics to Hold Annual Meeting of StockholdersThomson Reuters ONE(Wed, May 15)
- CYTOKINETICS INC FinancialsEDGAR Online Financials(Tue, May 14)
- SmithOnStocks Opines On Recent Biotech Newsat Seeking Alpha(Mon, May 13)
- CYTOKINETICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Cytokinetics' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 30)
- Cytokinetics, Inc. Earnings Call scheduled for 4:30 pm ET todayCCBN(Tue, Apr 30)
- Cytokinetics, Incorporated Reports First Quarter 2013 Financial ResultsThomson Reuters ONE(Tue, Apr 30)
- CYTOKINETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, Apr 30)
- A New Approach to Treating a Broken Heartat Motley Fool(Tue, Apr 30)
- Q1 2013 Cytokinetics, Inc. Earnings Release - 4:00 pm ETCCBN(Tue, Apr 30)
- The Fool Looks Aheadat Motley Fool(Sat, Apr 27)
- 5 Stocks Poised for Breakoutsat TheStreet(Fri, Apr 19)
- 2 High Risk Biotech Stocks Under $2 That Could Yield A High Rewardat Seeking Alpha(Wed, Apr 17)
- Cytokinetics to Announce First Quarter Results on April 30, 2013Thomson Reuters ONE(Tue, Apr 16)
- Cytokinetics: Key Issues For Beginning Phase III For Omecamtiv Mecarbil In Congestive Heart Failureat Seeking Alpha(Thu, Apr 11)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 26.96 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.39 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.10 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -0.20 |
|---|
Business Summary
Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
View More